Submit Deal

AMICUS THERAPEUTICS

HQ - Cranbury, New Jersey

Summary

Amicus Therapeutics, a biotechnology company developing therapies for Fabry disease and Pompe disease.

Deals Overview

Total Deals4

Valued Deals4

Total Value£ 4.46 B

Avg. Deal Size£ 1.11 B

Market Context

Subsidiaries

AMICUS THERAPEUTICS (GENE THERAPY BUSINESS)

1 transaction

Senior Management

Bradley Campbell
President and CEO
John F. Crowley
Chairman and CEO
Simon Harford
CFO

Sort

bradley campbell

President and CEO at AMICUS THERAPEUTICS

Manager

Deals

£ 4.38 B

Total Value

simon harford

CFO at AMICUS THERAPEUTICS

Manager

Deal

£ 352 M

Total Value

diana moore

Head of Global Corporate Communications at AMICUS THERAPEUTICS

Manager

Deals

£ 793 M

Total Value

daphne e. quimi

CFO at AMICUS THERAPEUTICS

Manager

Deals

£ 517 M

Total Value

john f. crowley

Chairman and CEO at AMICUS THERAPEUTICS

Manager

Deals

£ 517 M

Total Value

andrew faughnan

Executive Director, Investor Relations at AMICUS THERAPEUTICS

Manager

Deals

£ 4.46 B

Total Value

brendan mcevoy

Executive Director, External Communications at AMICUS THERAPEUTICS

Manager

Deal

£ 3.59 B

Total Value